Phase I study of imetelstat (GRN163L) in combination with paclitaxel (P) and bevacizumab (B) in patients (pts) with locally recurrent or metastatic breast cancer (MBC).

被引：0
|
作者：
Kozioff, M.
Sledge, G. W.
Benedetti, F. M.
Starr, A.
Wallace, J. A.
Stuart, M. J.
Gruver, D.
Miller, K.
机构：
[1] Ingalls Hosp, Harvey, IL USA
[2] Univ Chicago, Harvey, IL USA
[3] Indiana Univ, Simon Canc Ctr, Indianapolis, IN 46204 USA
[4] Genon Corp, Menlo Pk, CA USA
[5] Monroe Med Assoc, Harvey, IL USA
[6] Univ Chicago, St Marys Hosp, Monroe Med Assoc, Chicago, IL 60637 USA
[7] Indiana Univ, Melvin & Bren Simon Canc Ctr, Indianapolis, IN 46204 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2598
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Results of a Phase I Study of GRN163L, a Direct Inhibitor of Telomerase, in Patients with Relapsed and Refractory Multiple Myeloma (MM).
    Chanan-Khan, Asher Alban
    Munshi, Nikhil C.
    Hussein, Mohamad A.
    Elias, Laurence
    Benedetti, Fabio
    Smith, Jennifer
    Khor, Soo-Peang
    Huff, Carol A.
    BLOOD, 2008, 112 (11) : 1263 - 1263
  • [22] Safety of bevacizumab (BV) plus docetaxel (D) in patients (pts) with locally recurrent (LR) or metastatic breast cancer (mBC) who developed brain metastases during the AVADO phase III study
    Dirix, L. Y.
    Romieu, G.
    Provencher, L.
    Grimes, D.
    de Souzo, Viana L.
    Paterson, A.
    Mauriac, L.
    Kirsch, A.
    Pernas, S.
    Miles, D. W.
    CANCER RESEARCH, 2009, 69 (02) : 285S - 285S
  • [23] First-Line Bevacizumab in Combination with Capecitabine or Paclitaxel for HER2-Negative Locally Recurrent or Metastatic Breast Cancer (LR/MBC): A Randomized Phase Ill Trial.
    Beslija, S.
    Brodowicz, T.
    Greil, R.
    Inbar, M. J.
    Kahan, Z.
    Kaufman, B.
    Lang, I.
    Steger, G. G.
    Stemmer, S. M.
    Zielinski, C.
    Zvirbule, Z.
    CANCER RESEARCH, 2011, 71
  • [24] Phase II Study of Bevacizumab in Combination with Docetaxel and Capecitabine for the First-Line Treatment of Patients with Locally Recurrent or Metastatic Breast Cancer
    Musolino, A.
    Bisagni, G.
    De Matteis, A.
    Nuzzo, F.
    Ardizzoni, A.
    Crino, L.
    Gamucci, T.
    Passalacqua, R.
    Gnoni, R.
    Boni, C.
    CANCER RESEARCH, 2010, 70
  • [25] Weekly paclitaxel (T) and cisplatin (P) in patients (Pts) with metastatic breast cancer (Mbc) previously treated with antraciclines (A).
    Martinez, LC
    Campelo, RG
    Curbera, GA
    Ayerbes, MV
    Novoa, SA
    Hernández, PA
    Aparicio, LA
    ANNALS OF ONCOLOGY, 2000, 11 : 38 - 38
  • [26] Phase II trial combining nab-paclitaxel (NP), gemcitabine (G), and bevacizumab (B) in patients (pts) with metastatic breast cancer (MBC): NCCTG N0735
    Northfelt, D. W.
    Dueck, A. C.
    Flynn, T. P.
    Zander, P. J.
    Stella, P. J.
    Melnik, M.
    Pavey, E. S.
    Perez, E. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [27] Phase I study of escalating doses of edatrexate in combination with paclitaxel in patients with metastatic breast cancer
    D'Andrea, G
    Fennelly, D
    Norton, L
    Baselga, J
    Gilewski, T
    Hudis, C
    Moynahan, ME
    Raptis, G
    Sklarin, N
    Surbone, A
    Theodoulou, M
    Templeton, MA
    Yao, TJ
    Seidman, AD
    CLINICAL CANCER RESEARCH, 1999, 5 (02) : 275 - 279
  • [28] Clinical benefit of bevacizumab (BV) plus first-line docetaxel (D) in elderly patients (pts) with locally recurrent (LR) or metastatic breast cancer (mBC): AVADO study
    Pivot, X.
    Verma, S.
    Thomssen, C.
    Passos-Coelho, J. L.
    Latini, L.
    Ciruelos, E.
    Silva, M.
    von Moos, R.
    Chang, H.
    Miles, D. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [29] Phase I study of capecitabine in combination with paclitaxel in patients with previously treated metastatic breast cancer
    Villalona-Calero, M
    Blum, J
    Diab, S
    Elledge, R
    Khoury, P
    Kraynak, M
    Moczygemba, J
    Kromelis, P
    Impellizeri, K
    Griffin, T
    Von Hoff, D
    Rowinsky, E
    ANNALS OF ONCOLOGY, 1998, 9 : 97 - 97
  • [30] A phase I study of combination therapy with nanoparticle albumin-bound paclitaxel and cyclophosphamide in patients with metastatic or recurrent breast cancer
    Goro Kutomi
    Tousei Ohmura
    Fukino Satomi
    Hideki Maeda
    Hiroaki Shima
    Hidekazu Kameshima
    Minoru Okazaki
    Hideji Masuoka
    Kenichi Sasaki
    Koichi Hirata
    International Journal of Clinical Oncology, 2015, 20 : 474 - 479
12345